Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab versus Rebif in relapsing multiple sclerosis
NL-OMON43603Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Ocrevus arm with Rebif arm (2 arms). Primary endpoint: Annualized protocol-defined relapse rate at 96 weeks. Started Jun 2018; status: active, not recruiting.
02
Drugs
ocrelizumabinterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON43603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43603.